Programmed death‐ligand 1 (PD‐L1) protein expression in the pretreatment tumor tissue determines eligibility for immunotherapy targeting PD‐1 or PD‐L1 inhibitors with or without chemotherapy. Here, CD274 is linked to neoplasm.